

HPV vaccination: A vital step towards preventing cancer

Morgan Roupret*

Department of Prevention Medicine, Aston University, Birmingham, United Kingdom

INTRODUCTION

Human Papillomavirus (HPV) is a common sexually transmitted infection that can lead to severe health consequences, including various forms of cancer. In the last few decades, medical advancements have led to the development of vaccines that can protect against certain strains of HPV, significantly reducing the risk of these cancers. This article explores the importance of HPV vaccination as a critical tool in the prevention of HPV-related diseases, emphasizing its safety, efficacy, accessibility, and the potential for eradicating HPV-related cancers.

DISCUSSION

Understanding HPV and its link to cancer

Human Papillomavirus (HPV) is a group of more than 200 related viruses, many of which are sexually transmitted. It's incredibly common, with nearly everyone who is sexually active likely to be exposed to it at some point in their life. While most HPV infections clear on their own without causing any symptoms or harm, some high-risk strains can lead to various forms of cancer.

HPV and cervical cancer

Cervical cancer is the most well-known HPV-related cancer. High-risk HPV strains can cause persistent infections that lead to cervical cancer over time. Cervical cancer is the fourth most common cancer in women globally.

HPV and other cancers

HPV is also linked to other cancers, including anal, penile, vaginal, vulvar, and oropharyngeal cancers. The connection between these cancers and HPV has become increasingly evident over the years.

The HPV vaccines

To combat the threat of HPV-related cancers, scientists developed vaccines that target the most common and high-risk HPV strains. There are currently two HPV vaccines available: Gardasil 9 and Cervarix.

Gardasil 9: Gardasil 9 is the more widely used vaccine.

Address for correspondence:

Morgan Roupret,
Department of Prevention Medicine, Aston University,
Birmingham, United Kingdom
E-mail: morgan.roupret@psl.aphp.fr

Word count: 924 **Tables:** 00 **Figures:** 0 **References:** 00

Received: 04.09.2023, Manuscript No. IPACR-23-14205;

Editor assigned: 07.09.2023, PreQC No. P-14205;

Reviewed: 21.09.2023, QC No. Q-14205;

Revised: 09.10.2023, Manuscript No. R-14205;

Published: 19.10.2023, Invoice No. J-14205

It protects against nine HPV strains, including those responsible for most HPV-related cancers. The vaccine is administered in a series of two or three doses.

Cervarix: Cervarix is another HPV vaccine but targets only two high-risk HPV strains. It's primarily used in countries where the two targeted strains are more prevalent.

Safety of HPV vaccination

The safety of HPV vaccines has been extensively studied and monitored. Clinical trials and real-world data consistently support their safety.

Clinical trials: Before approval, both Gardasil 9 and Cervarix underwent rigorous clinical trials involving thousands of participants. These trials demonstrated the vaccines' safety and effectiveness.

Real-world experience: Since their introduction, millions of people have received HPV vaccines. Long-term safety monitoring has not shown any unexpected or severe side effects.

Common side effects

Like any vaccine, HPV vaccines can cause minor side effects such as pain at the injection site, fever, and dizziness. These side effects are temporary and far outweigh the potential health risks of HPV infection.

Efficacy of HPV vaccination: HPV vaccination is highly effective in preventing the targeted HPV strains and, by extension, the associated cancers.

Reduction in HPV infections: Vaccination has led to a significant decline in the prevalence of HPV strains targeted by the vaccines. This reduction indicates that HPV vaccination works in preventing infections.

Cervical cancer prevention

Cervical cancer rates have decreased in countries with high HPV vaccine coverage. This is a clear sign of the vaccine's efficacy in preventing a life-threatening cancer.

Herd immunity: High vaccine coverage creates herd immunity, further protecting those who cannot receive the vaccine for medical reasons.

Accessibility and equity: Ensuring HPV vaccines are accessible to all is essential in the fight against HPV-related cancers. Various initiatives aim to improve vaccine accessibility.

Global initiatives: Organizations like Gavi, the Vaccine Alliance, work to make HPV vaccines available in low-income countries. Global partnerships and initiatives promote equitable vaccine distribution.

National immunization programs

Many countries have integrated HPV vaccination into their national immunization programs. This ensures that

vaccines are provided free or at a reduced cost to eligible individuals.

School-based vaccination: Some countries implement school-based HPV vaccination programs, ensuring easy access for adolescents.

The eradication potential: HPV vaccination holds the promise of eradicating HPV-related cancers in the future. However, this goal requires widespread vaccine coverage and continued efforts.

Elimination vs eradication: Elimination aims to reduce the incidence of a disease to a very low level within a specific geographic area. Eradication is the complete and permanent removal of a disease worldwide.

Challenges to eradication: Achieving global eradication of HPV-related cancers presents challenges, such as vaccine hesitancy and health infrastructure limitations. Nevertheless, the reduction in cancer rates is a significant step towards this goal.

Continuing research

Ongoing research aims to improve vaccine delivery and coverage, especially in underserved populations. New technologies and strategies are being developed to enhance HPV vaccination efforts.

Overcoming vaccine hesitancy: Vaccine hesitancy remains a significant obstacle to achieving high HPV vaccine coverage. Public education and awareness campaigns are essential to counter misconceptions and fears.

Addressing concerns: Misinformation about vaccine safety and efficacy can contribute to hesitancy. Health authorities and healthcare professionals play a crucial role in addressing these concerns.

Public awareness: Raising public awareness about the link between HPV and cancer can motivate individuals to get vaccinated. Education campaigns should target parents, adolescents, and healthcare providers.

CONCLUSION

The development and widespread use of HPV vaccines represent a crucial step in the prevention of HPV-related cancers. These vaccines have proven to be safe and effective, and their accessibility continues to improve, helping to protect populations against this significant health threat. While challenges remain in achieving global eradication, the reduction in cancer rates demonstrates the positive impact of HPV vaccination. Public education and awareness efforts are essential in overcoming vaccine hesitancy, making HPV vaccination a key tool in the fight against HPV-related diseases and the pursuit of a healthier future.